{'fraction_non_alphanumeric': 0.039951573849878935, 'fraction_numerical': 0.03631961259079903, 'mean_word_length': 4.587837837837838, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Dobutamine pharmacokinetics in severe heart failure

Dobutamine pharmacokinetics was investigated in 7 patients with severe cardiac failure. Dobutamine was administered by a constant intravenous infusion at rates of 2 .5, 5.0, 7.5, and 10.0 µg/kg/min. Steady‐state plasma levels increased in proportion to the infusion rate, indicating that there was no saturation of the disposition processes. The average total body clearance was found to be 2.35 ± 1.01 L/min/m2. After termination of the final infusion, plasma levels of dobutamine were monitored to determine the elimination half‐life. The disappearance half‐life of dobutamine was calculated to be 2.37 ± 0.7 min and the distribution volume was 0.202 ± 0.084 L/kg. The limited data suggest that the volume of distribution of dobutamine was related to the extent of edema.